Navigation Links
Amgen's Denosumab and Eli Lilly's Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
Date:6/1/2009

Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen's novel agent denosumab and Eli Lilly's parathyroid hormone (PTH) analogue Forteo/Forsteo (teriparatide) will drive robust 4.3 percent annual growth in the osteoporosis drug market from 2013 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Osteoporosis finds that concerns about the long-term safety of bisphosphonates -- which currently dominate the market -- will help convince primary care physicians and specialists to switch patients to PTH analogues and novel agents such as denosumab. The uptake of denosumab, which has a convenient dosage regimen of bi-annual subcutaneous injections, will drive the agent to achieve blockbuster sales of $2 billion in 2018 for the treatment of osteoporosis and osteopenia. The report also forecasts that Forteo/Forsteo will achieve blockbuster status in 2018 with sales of approximately $2 billion. Forteo/Forsteo's uptake will be achieved as a result of its efficacy in reducing the frequency of fractures as well as the prevalent safety concerns about the bisphosphonates.

The report also finds that that the launches of third-generation selective estrogen receptor modulators (SERMs), most notably Eli Lilly's arzoxifene, will drive market growth. Physicians will increasingly prescribe these agents, particularly if they demonstrate significant efficacy in reducing nonvertebral fractures.

"Interviewed experts indicate that arzoxifene is the most promising of the third-generation SERMs, as they believe it may be as efficacious as Pfizer's Fablyn without increasing mortality," said Decision
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Virus Could Help Drive Obesity
2. Back to School Means Return of School Blood Drives
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
5. Customized virus kills brain tumor stem cells that drive lethal cancer
6. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
7. Cancer stem cell subpopulation drives metastasis of human pancreatic cancer
8. Brain Defect Helps Drive Fragile X Syndrome
9. Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment
10. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
11. Disabilities Rising Among Workers; Need for Employer-Driven Disability Awareness, Support Efforts Also Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 As Mirena lawsuit ... court, a new report has revealed that that the IUD ... & Drug Administration (FDA) adverse event reports since coming on ... Ohio, over 4.700 Mirena users have reported device dislocation or ... have reportedly experienced uterine perforations due to Mirena.* , “We ...
(Date:6/18/2013)... -- Lauren Sciences, a privately-held biotechnology company furthering ... announced today that it was independently recognized as ... V-Smart Platform, and selected as a Featured Company, ... , The report, " Early Stage Drug ... ," features companies MCD Group independently selected as ...
(Date:6/18/2013)... officially declared June as Lesbian, Gay, Bisexual ... advances in civil rights, sexual minority youth ... than their heterosexual peers, according to the ... Missouri psychology graduate student recently published recommendation ... youth, which could help improve psychological functioning ...
(Date:6/18/2013)... With Medicare penalties on hospitals with higher-than-expected rates ... more hospitals are evaluating the most accurate methods ... study appearing in the June issue of the ... finds that the American College of Surgeons ... to more accurate data tracking than another popular ...
(Date:6/18/2013)... Two weeks ago, eyes across America were glued to ... reported by CNN on June 6 in an article ... building scheduled to be demolished ended up burying a group ... persons succumbed to their injuries. It was a sad ... should serve as a reminder that the safety of Pennsylvania ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Sexual minority youth need specialized treatment from therapists 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 3Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 4Health News:Ensuring The Safety of Pennsylvania Worksites 2Health News:Ensuring The Safety of Pennsylvania Worksites 3
... Medicaid program is likely paying far more than necessary ... ones available, by ignoring international evidence-based lists of safe ... researchers at University of California, San Francisco. The ... in 40 states nationwide against the World Health Organization,s ...
... (HealthDay News) -- Hospitalization for further observation isn,t necessary for ... normal CT scans, a new study indicates. Researchers examined ... with minor blunt head trauma, who were treated at 25 ... Of those children, less than 1 percent had abnormal CT ...
... Reinberg HealthDay Reporter , FRIDAY, June 17 (HealthDay ... deaths in the United States in the past two decades, ... a dramatic decline between 1990 and 2007 -- nearly 900,000 ... "It,s getting better for the majority of cancers," said Dr. ...
... Women & Infants Hospital of Rhode Island has been ... by OptumHealth, an independent audit company. According to ... For complex medical conditions, the disparity is especially ... Centers of Excellence networks that provide access to clinically ...
... not protecting Arizonans from having problems paying medical bills, and ... care and prescription medicines, a new study has found. ... the American Journal of Public Health , after taking ... does not lower the odds of accruing debt related to ...
... FRIDAY, June 17 (HealthDay News) -- Home learning experiences such ... readiness to start school, researchers say. The new study ... families with household incomes at or below the federal poverty ... 2, 3 and 5 years, the New York University researchers ...
Cached Medicine News:Health News:US Medicaid drug lists cost more, deliver less 2Health News:US Medicaid drug lists cost more, deliver less 3Health News:Nearly 900,000 Fewer Cancer Deaths Since 1990: Report 2Health News:Nearly 900,000 Fewer Cancer Deaths Since 1990: Report 3Health News:Medical debt occurs despite insurance, UA study shows 2Health News:Reading With Mom Can Boost Kindergarten Readiness 2
(Date:6/18/2013)... 2013  Healthgrades, the leading online resource that ... physicians and hospitals, today issued the Healthgrades ... Healthcare Decisions to Get Your Best Outcome . The ... maternity care, gynecologic surgery, as well as hospitals ... 15 of the most common hospital-based conditions and ...
(Date:6/18/2013)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the ... a general corporate update in conjunction with its 2013 Annual ... at 2:10 p.m. Pacific Time in Carlsbad, CA. ... as follows: 2:00 p.m. – 2:10 p.m. Annual Meeting of ... 2013) 2:10 p.m. – 3:15 p.m. Corporate Presentation – ...
(Date:6/17/2013)... , June 17, 2013 DNAtrix Inc., ... CEO will present clinical data on the company,s lead ... in Quebec City, Canada on ... , DNAtrix,s CEO and a leader in the field ... clinical study entitled A PHASE I TRIAL OF A ...
Breaking Medicine Technology:Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 2Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 3Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 4Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2
... 24 The National Community Pharmacists ... Jaeger as Executive Vice President and CEO, heralding ... the association,s recent accomplishments and lead it to ... of, independent community pharmacies and the patients they ...
... N.J., Oct. 23, 2010 Arena Pharmaceuticals, Inc. (Nasdaq: ... Food and Drug Administration (FDA) issued a Complete Response Letter ... is intended for weight management, including weight loss and maintenance ... Index, or BMI, >/= 30) or patients who are overweight ...
Cached Medicine Technology:NCPA Announces Kathleen Jaeger as CEO 2FDA Issues Complete Response Letter for Lorcaserin New Drug Application 2FDA Issues Complete Response Letter for Lorcaserin New Drug Application 3FDA Issues Complete Response Letter for Lorcaserin New Drug Application 4FDA Issues Complete Response Letter for Lorcaserin New Drug Application 5FDA Issues Complete Response Letter for Lorcaserin New Drug Application 6
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 16 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 15 mm....
Medicine Products: